A Look at ProQR Therapeutics N.V. (PRQR) Shares in the Recent Past Indicates Growth

ProQR Therapeutics N.V. (NASDAQ: PRQR) stock fell -6.41% on Monday to $2.63 against a previous-day closing price of $2.81. With 3.0 million shares changed hands, the volume of the stock remained heavier than its average volume of 2.9 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $2.8300 whereas the lowest price it dropped to was $2.5000. The 52-week range on PRQR shows that it touched its highest point at $6.15 and its lowest point at $0.53 during that stretch. It currently has a 1-year price target of $3.21. Beta for the stock currently stands at 0.19.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…


Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of PRQR was down-trending over the past week, with a drop of -23.32%, but this was up by 62.35% over a month. Three-month performance surged to 200.13% while six-month performance rose 230.82%. The stock lost -52.36% in the past year, while it has lost -28.92% so far this year. A look at the trailing 12-month EPS for PRQR yields -1.09 with Next year EPS estimates of -0.42. For the next quarter, that number is -0.17. This implies an EPS growth rate of -3.20% for this year and 55.60% for next year.

Float and Shares Shorts:

At present, 71.38 million PRQR shares are outstanding with a float of 62.46 million shares on hand for trading. On Oct 13, 2022, short shares totaled 1.25 million, which was 1.75% higher than short shares on Sep 14, 2022. In addition to Dr. Domenico Valerio Ph.D. as the firm’s Founder & Independent Chairman of Supervisory Board, Mr. Daniel Anton de Boer serves as its Founder, CEO & Member of Management Board.

Institutional Ownership:

Through their ownership of 43.60% of PRQR’s outstanding shares, institutional investors have minority control over the company. Other institutions hold 17.62% of PRQR, in contrast to 12.22% held by mutual funds. Shares owned by individuals account for –. As the largest shareholder in PRQR with 7.50% of the stake, Privium Fund Management BV holds 5,344,446 shares worth 5,344,446. A second-largest stockholder of PRQR, Adage Capital Management LP, holds 3,300,000 shares, controlling over 4.63% of the firm’s shares. Opaleye Management, Inc. is the third largest shareholder in PRQR, holding 3,115,000 shares or 4.37% stake. With a 6.69% stake in PRQR, the Aescap Life Sciences is the largest stakeholder. A total of 4,765,659 shares are owned by the mutual fund manager. The JPMorgan Funds – Thematics – Gene, which owns about 1.35% of PRQR stock, is the second-largest Mutual Fund holder. It holds 961,511 shares valued at 3.56 million. Fidelity Funds SICAV – European S holds 1.26% of the stake in PRQR, owning 899,250 shares worth 3.33 million.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for PRQR since 8 analysts follow the stock currently. There are 3 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 4 believe that the stock is worth HOLDING, 1 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With PRQR analysts setting a high price target of $5.00 and a low target of $0.94, the average target price over the next 12 months is $3.27. Based on these targets, PRQR could surge 90.11% to reach the target high and fall by -64.26% to reach the target low. Reaching the average price target will result in a growth of 24.33% from current levels.

EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. PRQR will report FY 2022 earnings on 02/22/2024. Analysts have provided yearly estimates in a range of -$0.88 being high and -$1.06 being low. For PRQR, this leads to a yearly average estimate of -$0.94. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. ProQR Therapeutics N.V. surprised analysts by -$0.13 when it reported -$0.34 EPS against a consensus estimate of -$0.21. The surprise factor in the prior quarter was $0.00. Based on analyst estimates, the high estimate for the next quarter is -$0.13 and the low estimate is -$0.27. The average estimate for the next quarter is thus -$0.18.

Leave a Comment

Your email address will not be published. Required fields are marked *